Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.42 |
| ▸ | CTSK | P43235 | 6/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11901907 | 0.92 | CTSS (0.40) | CTSSCTSKPOLBMEN1KMT2A | |
| SCHEMBL11900734 | 0.91 | CTSS (0.42) | CTSSCTSKJAK2JAK1TRPA1 | |
| SCHEMBL11901739 | 0.88 | CTSS (0.39) | CTSSCTSKPOLBMEN1KMT2A | |
| SCHEMBL11902408 | 0.78 | AAK1 (0.37) | TRPA1MEN1KMT2ASCN9ACACNA1B | |
| SCHEMBL11901757 | 0.74 | AAK1 (0.39) | CTSSCTSKTRPA1POLBMEN1 | |
| SCHEMBL11901759 | 0.74 | AAK1 (0.39) | CTSSCTSKTRPA1POLBMEN1 | |
| SCHEMBL22312263 | 0.73 | CTSS (0.43) | CTSSCTSKTRPA1MEN1KMT2A | |
| SCHEMBL11901926 | 0.69 | KMT2A (0.39) | CTSSCTSKTRPA1MEN1KMT2A | |
| SCHEMBL11900730 | 0.67 | CTSS (0.39) | CTSSCTSKTRPA1MEN1KMT2A | |
| SCHEMBL12472694 | 0.67 | CTSS (0.39) | CTSSCTSKTRPA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | CTSS 2609/4885CTSK 1821/4885JAK2 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.